

AGENDA

Translational Advances in Cancer Prevention Agent Development (TACPAD)

4th Biennial Virtual Meeting

Sponsored by the Division of Cancer Prevention, NCI

DATE: September 28-30, 2026

Times listed are for Eastern Daylight Savings Time

Day 1, September 28th (11:00 AM to 4:30 PM)

- | | |
|------------------------------|--|
| 11:00-11:10 AM | Welcome
Altat Mohammed, Ph.D., Meeting Co-Organizer, DCP/NCI
Brian Cholewa, Ph.D., Meeting Co-Organizer, DCP/NCI |
| 11:10-12:00 PM | Plenary Talk

NCI Division of Cancer Prevention: Overview and Research Opportunities
Lori Minasian, MD., Deputy Director, DCP/NCI |
| 12:00-3:00 PM | Session I
Emerging Targets, Vaccines and Immunomodulatory Agents for Cancer Prevention
<i>Co-Chairs:</i> Nicholas Arpaia and Anda Vlad |
| 20 minutes talk, 10 min Q&As | |
| 12:00-12:30 PM | Delivering cancer prevention vaccines into the clinic
Sarah Blagden, BSc, FRCP, PhD., University of Oxford |
| 12:30-1:00 PM | Programmable probiotics for personalized cancer immunotherapy and immunoprevention
Nicholas Arpaia, Ph.D., Columbia University Irving Medical Center |
| 1:00-1:30 PM | Lunch |
| 1:30-2:00 PM | Immune determinants modulating cancer development in Lynch Syndrome
Robert Samstein, MD, Ph.D., Icahn School of Medicine at Mount Sinai |
| 2:00-2:30 PM | Intercepting pancreatic cancer progression through adenosine pathway modulation
Jennifer Bailey-Lundberg, Ph.D., University of Texas HSC Houston |
| 2:30-3:00 PM | Manufacture of Epstein-Barr Virus Vaccine
Andrew McGuire, PhD., Fred Hutchinson Cancer Center |
| 3:00-3:30 PM | Break |

- 3:30-4:30 PM **Early Investigator Flash Talks**
Co-Chairs: Altaf Mohammed and John Clifford
- 10 minutes talk, 5 min Q&As
- 3:30-3:45 PM **From TRAIL modulation to immune interception: Doradaviprone (ONC201) for colorectal cancer prevention**
 Alexander Raufi, MD., The Warren Alpert Medical School of Brown University
- 3:45-4:00 PM **Harnessing nutrition to enhance cancer immunotherapy**
 Nicholas Collins, Ph.D., Weill Cornell Medicine
- 4:00-4:15 PM **The perfect pair: Integrating drug synergy and precision nanomedicine for smarter cancer management**
 Preshita Desai, B. Pharm, PhD., Western University of Health Sciences
- 4:15-4:30 PM **Bladder cancer prevention**
 Venkateshwar Madka, Ph.D., University of Oklahoma
- Adjourn**

Day 2, September 29th (11:00 AM to 5:00 PM)

- 11:00-1:30 PM **Session II: Molecularly Targeted Novel Agents for Cancer Prevention and Interception**
Co-Chairs: Michael Buszczak and Asad Umar
- 20 minutes talk, 10 min Q&As
- 11:00-11:30 AM **Investigating novel targets for topical immunoprevention of skin cancer**
 Clara Curiel-Lewandrowski, MD., University of Arizona
- 11:30-12:00 PM **Mitochondria-targeted atovaquone for cancer immunoprevention**
 Ming You, M.D., Ph.D., Houston Methodist Research Institute
- 12:00-12:30 PM **Developing ribosome biogenesis inhibitors for the prevention of cancer**
 Michael Buszczak, Ph.D., UT Southwestern Medical Center
- 12:30-1:00 PM **Novel Pan-RAS inhibitors for pancreatic cancer prevention and interception**
 Gary Piazza, Ph.D., Auburn University
- 1:00-1:30 PM **Discovery and development of LFA-9 for CRC interception**
 Chinthalapally Rao, Ph.D., University of Oklahoma

- 1:30-2:00 PM Lunch**
- 2:00-4:00 PM Session III: Clinically Relevant Alternative Models for Cancer Prevention**
Co-Chairs: Brian Cholewa and Kajal Biswas
- 20 minutes talk, 10 min Q&As
- 2:00-2:30 PM Organoids for Cancer Prevention, Interception and Treatment**
David Tuveson, PhD., Cold Spring Harbor Laboratory
- 2:30-3:00 PM New approach methodologies to clinical trial-in-a-dish**
Joseph Wu, MD, PhD., Stanford University School of Medicine
- 3:00-3:30 PM Microfluidics in biomedical research: lab-on-a-chip microtechnologies**
David Beebe, Ph.D., University of Wisconsin
- 3:30-4:00 PM Modeling cancer prevention and interception: Organoid platforms for preclinical vaccine and immunotherapy evaluation**
Yurong Song, PhD., Leidos
- 4:00-5:00 PM Meet with the NCI Program Staff**
- Biomarkers – Guillermo Marquez and Sydney Fu
 - Prevention/Interception – John Clifford and Anda Vlad
 - Clinical trials – Goli Samimi and Eileen Dimond

Adjourn

Day 3, September 30th (11:00 AM to 4:30 PM)

- 11:00-1:30 PM Session IV: Cancer Prevention-Interception Clinical Trials**
Co-Chairs: Eduardo Vilar-Sanchez and Goli Samimi
- 20 minutes talk, 10 min Q&As
- 11:00-11:30 AM Overview of DCP Supported Clinical Trials**
Goli Samimi, Ph.D., DCP/NCI
- 11:30-12:00 PM Nous 209 vaccine trial**
Eduardo Vilar-Sanchez, MD, Ph.D., MD Anderson Cancer Center
- 12:00-12:30 PM The Tamoxifen RENAISSANCE: dosing, metabolites & drug delivery**
Seema Khan, MD., Northwestern Feinberg School of Medicine
- 12:30-1:00 PM Reprogramming precancer for prevention/interception of gastric carcinogenesis**
James Goldenring, MD, PhD., AGAF

- 1:00-1:30 PM **Daily exemestane in women with endometrial intraepithelial neoplasia or low grade endometrial cancer**
Britt Erickson, MD., University of Minnesota
- 1:30-2:00 PM **Break**
- 2:00-4:30 PM **Session V: Panel Discussion**
Biomarkers as Intermediate End Points for Cancer Prevention Clinical Trials

Co-Chairs: Brandy Heckman-Stoddard and Goli Samimi
- 2:00-2:25 PM **Biomarkers as intermediate end points for oncology clinical trials**
Nathan Standifer, PhD., Vera Therapeutics, Inc.
- 2:25-2:50 PM **Status on current intermediate end points for cancer prevention clinical trials**
Brandy Heckman-Stoddard, Ph.D., DCP/NCI
- 2:50-4:30 PM **Panel Discussion**

Closing Remarks and Adjourn

Brian Cholewa, Ph.D., Meeting Co-Organizer, DCP/NCI

Altaf Mohammed, Ph.D., Meeting Co-Organizer, DCP/NCI